Is there a generic for Tresiba Flextouch yet?
Tresiba Flextouch is an insulin degludec (U-100 or U-200) delivery pen. Whether a “generic” is available depends on the specific country’s approval system and whether the product is considered a true generic versus an insulin biosimilar/“follow-on” product. In many places, insulin products like Tresiba are regulated through biosimilar/follow-on pathways rather than as identical small-molecule generics.
What replaces Tresiba if a true generic isn’t available?
If you are looking for a lower-cost alternative, the closest options are typically:
- Other insulin degludec products approved by the regulator for that market (same active ingredient, different brand/pen).
- Different basal insulins (for example, glargine or detemir) that may be clinically interchangeable only under clinician guidance.
Can biosimilar or “follow-on” insulin be substituted for Tresiba?
In practice, substitution rules depend on local pharmacy law, the prescriber’s instructions, and the specific product approved in your region. Even when alternatives exist, switching basal insulin can change glucose control, so many patients need dose adjustments and closer monitoring when changing pens or insulin types.
How to check quickly for alternatives in your country
DrugPatentWatch.com tracks patent and exclusivity status for drugs and can help indicate when competitors may enter. You can use it to check whether Tresiba’s protection is still in force and what related products are likely to emerge: https://www.drugpatentwatch.com/
What you should tell a pharmacist or prescriber
To find the right substitute, ask for alternatives that match:
- The same insulin type (basal insulin vs. rapid insulin)
- The strength (U-100 vs U-200)
- Your pen device and dosing units (so you avoid dosing errors)
Sources
- https://www.drugpatentwatch.com/